Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 1/20 | 0.80 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.80 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.80 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.80 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.80 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.80 |
| ▸ | TAS2R14 | Q9NYV8 | 11/20 | 0.63 |
| ▸ | PTGES | O14684 | 2/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287441 | 0.89 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1287436 | 0.86 | PSEN1 (0.74) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1287458 | 0.86 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15396086 | 0.84 | TAS2R14 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10206702 | 0.83 | PSEN1 (0.73) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1674868 | 0.82 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5117441 | 0.79 | TAS2R14 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1673453 | 0.79 | PSEN1 (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5117430 | 0.79 | TAS2R14 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1674421 | 0.79 | TAS2R14 (0.64) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310384-A1 | Sulfonamide-Containing Compounds | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130310384-A1 | Sulfonamide-Containing Compounds | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2012047926-A2 | SULFONAMIDE-CONTAINING COMPOUNDS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012047926-A2 | SULFONAMIDE-CONTAINING COMPOUNDS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310384-A1 | Sulfonamide-Containing Compounds | BACE1, BACE2, GSAP | PSEN1 4/4885PSEN2 5/4885APH1B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.